Cellmid (ASX:CDY) has announced the appointment of Dr Bryce Vissel as Chairman of its Scientific Advisory Board.
Dr Vissel is currently the Head of the Neurodegenerative Diseases research group at the Garvan Institute of Medical Research as well as Conjoint Senior Lecturer at St Vincent's Clinical School, Faculty of Medicines, University of NSW. He previously worked for a decade at the prestigious Salk Institute in the US, widely recognised as the world's leading neuroscience laboratory.
Dr Vissel was recruited by the Garvan Institute to establish and lead research in brain and spinal cord disorders and repair.
His research has been internationally recognised, said Cellmid, including through the Fulbright, Lierbermann and BIOFIRST awards. Dr Vissel has published more than 50 peer-reviewed papers.
"We are delighted to welcome Dr Vissel as the leader of our Scientific Advisory Board," said Cellmid CEO, Maria Halasz. "Dr Viisel is a world-class researcher and his outstanding medical research experience will be invaluable in guiding Cellmid's therapeutic development programs toward clinical success."
According to Dr Vissel, "Cellmid's sharp focus on midkine underpins a range of therapeutic development programs for the company. This is because manipulating midkine therapeutically offers important potential for treating a range of diseases.
"My goal is to help realise this potential so that patients can benefit from the robust science underlying the company's drug development programs," he said.